PYXIS ONCOLOGY INC. - COMMON STOCK

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

27 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

21 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

13 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

07 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

05 Mar 2024 16:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces $50 Million Private Placement

27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

28 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

07 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

27 Sep 2023 09:18:58 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

31 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Pyxis Oncology Successfully Completes Acquisition of Apexigen

23 Aug 2023 08:35:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

11 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2023 17:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

30 May 2023 08:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Acquire Apexigen

24 May 2023 06:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Mar 2023 17:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

22 Mar 2023 06:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

16 Mar 2023 07:30:00 By Nasdaq GlobeNewswire